Skip to content Skip to sidebar Skip to footer
Home / Video / Noxopharm (ASX:NOX): Interview with CEO Graham Kelly

Noxopharm (ASX:NOX): Interview with CEO Graham Kelly

We talked with Graham Kelly about Noxopharm’s clinical success with Veyonda and in particular its synergies with radiation therapy. Veyonda is a drug that seems to work in a wide variety of cancers.

 

 

 

© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here